Core Viewpoint - The announcement of the second employee stock ownership plan by TianKang aims to enhance long-term incentive mechanisms, improve employee cohesion and corporate competitiveness, and deeply bind the interests of the company, shareholders, and employees [1] Summary by Relevant Sections Employee Stock Ownership Plan - The scale of the employee stock ownership plan is set between RMB 150 million and RMB 200 million, with an average purchase price based on the closing price of RMB 33.77 per share on June 20, 2025, leading to a minimum of approximately 4.44 million shares and a maximum of about 5.92 million shares, accounting for no more than 1.39% of the total share capital as of the announcement date [1] - The holding period for the stock is strictly regulated, with a minimum of 12 months required [1] Market Confidence and Stock Performance - Industry insiders highlight three key points regarding TianKang's equity incentive: the stock will be sourced through secondary market purchases, the buy-in scale is significant, and the plan reflects strong confidence in future development [2] - TianKang's stock price has surged by 130% this year, ranking fourth among innovative drug concept stocks [2] Innovation and Clinical Development - The collective rise of innovative drug leaders reflects a systematic re-evaluation of the long-term value of R&D investments, driven by expectations of industry upgrades rather than solely academic data disclosures [3] - TianKang's innovative drug CKBA for vitiligo has completed 100% subject enrollment in its Phase II clinical trial, with plans to explore additional indications in the next 3-5 years [3] Growth Areas - The company is focusing on several growth areas, including gastrointestinal drugs, sexual health, and ophthalmology [4] - In the gastrointestinal sector, TianKang aims to expedite the registration process for its product and target over RMB 1 billion in sales within 3-5 years [4] - The sexual health segment features leading products with significant market presence, and a new product is expected to enhance the company's portfolio [4] - In ophthalmology, the company is progressing with clinical trials for a product aimed at treating presbyopia, which could become the first of its kind in China [4] Overall Outlook - TianKang's employee stock ownership plan reflects the company's strong confidence in future growth, driven by innovation and clinical needs, while building high-value competitive barriers in core areas [5] - As key projects move towards commercialization, the company is expected to generate new performance growth points and enter a new growth cycle [5]

证券代码：301263 证券简称：泰恩康 广东泰恩康医药股份有限公司投资者关系活动记录表 编号：投-003 | 投资者关系活动 | □特定对象调研 □分析师会议 | | --- | --- | | | □媒体采访 √业绩说明会 | | 类别 | □新闻发布会 □路演活动 | | | □现场参观 □其他 | | 参与单位名称及 | 线上参与泰恩康 2024 年度网上业绩说明会的投资者 | | 人员姓名 | | | 时间 | 2025 年 05 月 12 日（星期一）15:00-16:00 | | 地点 | "约调研"小程序 | | 上市公司接待人 | 董事长、总经理：郑汉杰先生 | | | 董事、副总经理兼董事会秘书：李挺先生 | | 员姓名 | 财务总监：周桂惜女士 | | | 独立董事：彭朝辉先生 | | | 保荐代表人：徐振宇先生 | | 投资者关系活动 | 1、问：创新药 白癜风适应症已完成全部受试者入组， CKBA | | | 公司预计该创新药上市后，请问市场前景如何，对公司未来业绩 | | | 增长的贡献程度预计有多大？ | | | 年 软膏白癜风 期临 答：投资者您好，2024 10 月，CKBA ...

当前，我国医药行业已进入深度调整期，存量市场竞争愈发激烈。 近日东北制药（000597）披露的2024年报显示，报告期内公司实现营收75.03亿元，实现归母净利润4.1 亿元，实现扣非净利润3.12亿元。其中，归母净利润、扣非净利润同比分别增长14.34%、18.97%。此 外，公司经营活动产生的现金流量净额为7.59亿元，同比增长29.32%。东北制药经营质量稳步提升，发 展底盘持续加固，彰显了公司在复杂市场环境下强大的盈利能力和经营韧性。 经营质量稳步提升 东北制药是我国重要的药品生产与出口基地。拥有400多种化学原料药、医药中间体和制剂产品，主导 产品远销全球100多个国家和地区。 2024年，东北制药整体运营质量不断提高，公司营业总成本较上年显著降低，优势产品销售继续保持较 强竞争力，整体利润实现稳健增长。其中，收入端，制剂销售充分发挥"原料药+制剂"一体化优势，持 续提升产业链产品的市场竞争力，借助集采"以价换量"模式，进一步拉动生产需求，并通过调整优化产 品结构模式，提升高毛利率产品占比；原料销售方面，深挖产品潜力，积极开拓海外市场，2024年公司 出口收入同比增长26.30%。成本费用端，公司将 ...

Core Viewpoint - Northeast Pharmaceutical Group Co., Ltd. has shown continuous improvement in profitability, driven by market expansion and innovation in research and development [2][4]. Financial Performance - In the 2024 annual report, the company reported operating revenue of 7.503 billion yuan, a slight decrease year-on-year; net profit reached 410 million yuan, an increase of 14.34%; and non-net profit was 312 million yuan, up 18.97% [2]. - Both net profit and non-net profit have achieved four consecutive years of growth, reaching the highest levels since 2010 [2]. Dividend Distribution - The company plans to distribute a cash dividend of 1 yuan (including tax) for every 10 shares to all shareholders [3]. Competitive Advantages - Northeast Pharmaceutical is a significant drug production and export base in China, with integrated production bases for raw materials and formulations [4]. - The company has a diverse product line covering ten major series, including vitamins and anti-infection drugs, with products exported to over 100 countries and regions [4]. - The company increased its R&D investment to 149 million yuan, a year-on-year growth of 7.55% [4][5]. Innovation and Product Development - In 2024, the company successfully obtained one innovative drug candidate and approved five generic drugs for production [5]. - The company received approval for raw material drug listings and registered certificates for several new products, enhancing its product portfolio [5]. - The company’s raw materials, such as L-carnitine and vitamin C, received CEP certification from the European Medicines Agency, allowing sales in the EU high-end pharmaceutical market [5]. Export Business - The export business generated revenue of 902 million yuan in 2024, reflecting a year-on-year increase of 26.30%, with a gross margin growth of 5.89% [6]. Strategic Acquisition - The company is expanding into the biopharmaceutical sector by acquiring Beijing Dingcheng Peptide Source Biotechnology Co., Ltd., focusing on cell immunotherapy technology [7][8]. - Dingcheng Peptide Source has developed a complete technical platform for TCR-T and CAR-T cell therapy products targeting various cancers [7]. - This acquisition is expected to enhance the company's competitiveness in the biopharmaceutical field and accelerate the R&D and commercialization of innovative drugs [8].